Campolo Michela, Casili Giovanna, Biundo Flavia, Crupi Rosalia, Cordaro Marika, Cuzzocrea Salvatore, Esposito Emanuela
1 Department of Chemical, Biological, Pharmacological and Environmental Sciences, University of Messina , Messina, Italy .
2 Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine , St. Louis, Missouri.
Antioxid Redox Signal. 2017 Sep 10;27(8):453-471. doi: 10.1089/ars.2016.6800. Epub 2017 Jan 27.
Oxidative stress plays a key role in Parkinson disease (PD), and nuclear transcription factor related to NF-E2 (Nrf-2) is involved in neuroprotection against PD. The aim of the present study was to investigate a role for nuclear factor-κB (NF-κB)/Nrf-2 in the neurotherapeutic action of dimethyl fumarate (DMF) in a mouse model of PD and in vitro in SHSY-5Y cells.
Daily oral gavage of DMF (10, 30, and 100 mg/kg) significantly reduced neuronal cell degeneration of the dopaminergic tract and behavioral impairments induced by four injections of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Moreover, treatment with DMF prevented dopamine depletion, increased tyrosine hydroxylase and dopamine transporter activities, and also reduced the number of α-synuclein-positive neurons. Furthermore, DMF treatment upregulated the Nrf-2 pathway, increased NeuN/Nrf-2 cell number in the striatum, induced activation of manganese superoxide dismutase and heme oxygenase-1, and regulated glutathione levels. Moreover, DMF reduced interleukin 1 levels, cyclooxygenase 2 activity, and nitrotyrosine neuronal nitrite oxide synthase expression. This treatment also modulated microglia activation, restored nerve growth factor levels, and preserved microtubule-associated protein 2 alterations. The protective effects of DMF treatment, via Nrf-2, were confirmed in in vitro studies, through inhibition of Nrf-2 by trigonelline.
These findings demonstrate that DMF, both in a mouse model of PD and in vitro, provides, via regulation of the NF-κB/Nrf-2 pathway, novel cytoprotective modalities that further augment the natural antioxidant response in neurodegenerative and inflammatory disease models.
These results support the thesis that DMF may constitute a promising therapeutic target for the treatment of PD. Antioxid. Redox Signal. 27, 453-471.
氧化应激在帕金森病(PD)中起关键作用,与NF-E2相关的核转录因子(Nrf-2)参与对PD的神经保护。本研究旨在探讨核因子κB(NF-κB)/Nrf-2在富马酸二甲酯(DMF)对PD小鼠模型及体外SHSY-5Y细胞的神经治疗作用中的作用。
每日口服DMF(10、30和100mg/kg)可显著减少四次注射多巴胺能神经毒素1-甲基-4-苯基-1,2,3,6-四氢吡啶所致的多巴胺能神经通路神经元细胞变性及行为障碍。此外,DMF治疗可防止多巴胺耗竭,增加酪氨酸羟化酶和多巴胺转运体活性,并减少α-突触核蛋白阳性神经元数量。此外,DMF治疗上调Nrf-2通路,增加纹状体中NeuN/Nrf-2细胞数量,诱导锰超氧化物歧化酶和血红素加氧酶-1活化,并调节谷胱甘肽水平。此外,DMF降低白细胞介素1水平、环氧合酶2活性及硝基酪氨酸神经元型一氧化氮合酶表达。该治疗还调节小胶质细胞活化,恢复神经生长因子水平,并维持微管相关蛋白2改变。通过胡芦巴碱抑制Nrf-2,在体外研究中证实了DMF治疗通过Nrf-2产生的保护作用。
这些发现表明,DMF在PD小鼠模型及体外,通过调节NF-κB/Nrf-2通路,提供了新的细胞保护方式,进一步增强了神经退行性和炎症性疾病模型中的天然抗氧化反应。
这些结果支持DMF可能成为治疗PD的有前景的治疗靶点这一论点。《抗氧化与氧化还原信号》27卷,453 - 471页。